Explore the vast range of titles available.

The ITER Neutral Beam Test Facility (NBTF), called PRIMA (Padova Research on ITER Megavolt Accelerator), is hosted in Padova, Italy and includes two experiments: MITICA, the full-scale prototype of the ITER heating neutral beam injector, and SPIDER, the full-size radio frequency negative-ions source. The NBTF realization and the exploitation of SPIDER and MITICA have been recognized as necessary to make the future operation of the ITER heating neutral beam injectors efficient and reliable, fundamental to the achievement of thermonuclear-relevant plasma parameters in ITER. This paper reports on design and R&D carried out to construct PRIMA, SPIDER and MITICA, and highlights the huge progress made in just a few years, from the signature of the agreement for the NBTF realization in 2011, up to now-when the buildings and relevant infrastructures have been completed, SPIDER is entering the integrated commissioning phase and the procurements of several MITICA components are at a well advanced stage.

The experimental fusion reactor ITER will feature two (or three) heating neutral beam injectors (NBI) capable of delivering 33(or 50) MW of power into the plasma. A NBI consists of a plasma source for production of negative ions (extracted negative ion current up to 329 A/m 2 in H and 285 A/m 2 in D) then accelerated up to 1 MeV for one hour. The negative ion beam is neutralized, and the residual ions are electrostatically removed before injection. The beamline was designed for a beam divergence between 3 and 7 mrad. The ion source in ITER NBIs relies on RF-driven, Inductively-Coupled Plasmas (ICP), based on the prototypes developed at IPP Garching; RF-driven negative-ion beam sources have never been employed in fusion devices up to now. The recent results of SPIDER, the full size ITER NBI ion source operating at NBTF in Consorzio RFX, Padova, measure a beamlet divergence minimum of 12mrad and highlighted beam spatial non-uniformity. SPIDER results confirmed the experimental divergence found in smaller prototype sources, which is larger compared to filament-arc ion sources. Although prototype experiments have shown that the extracted current requirement can be achieved with minor design improvements, the beamlet divergence is expected to marginally achieve the design value of 7 mrad, which in multi-grid long accelerators results in unexpected heat loads over the accelerator grids. A contributor to the beam divergence is the energy/temperature of the extracted negative ions, so it is believed that plasma differences between the two source types play a role. Research is focused on the plasma parameters in the ion source. One RF driver, identical to the ones used in SPIDER, installed in a relatively small-scale experimental set-up, inherently more flexible than large devices, is starting operations devoted to the investigation of the properties of RF-generated plasmas, so as to contribute to the assessment of negative ion precursors, and of their relationship with the plasma parameters, particularly when enhancing plasma confinement. The scientific questions, that have arisen from the preliminary results of SPIDER, guided the design of the test stand, which are described in this contribution, together with the diagnostic systems and related simulation tools. The test stand, which shares with the larger experiment all the geometrical features and constraints, will allow technological developments and optimized engineering solutions related to the ICP design for the ITER NBIs.

ITER envisages the use of two heating neutral beam injectors plus an optional one as part of the auxiliary heating and current drive system. The 16.5 MW expected neutral beam power per injector is several notches higher than worldwide existing facilities. A Neutral Beam Test Facility (NBTF) was established at Consorzio RFX, exploiting the synergy of two test beds, SPIDER and MITICA. SPIDER is dedicated to developing and characterizing large efficient negative ion sources at relevant parameters in ITER-like conditions: source and accelerator located in the same vacuum where the beam propagates, immunity to electromagnetic interferences of multiple radio-frequency (RF) antennas, avoidance of RF-induced discharges on the outside of the source. Three years of experiments on SPIDER have addressed to the necessary design modifications to enable full performances. The source is presently under a long shut-down phase to incorporate learnings from the experimental campaign. Parallelly, developments on MITICA, the full-scale prototype of the ITER NBI featuring a 1 MV accelerator and ion neutralization, are underway including manufacturing of in-vessel components, while power supplies and auxiliary plants are already under final testing and commissioning. Integration, commissioning and tests of the 1MV power supplies are essential for this first-of-kind system, unparalleled both in research and industry field. The integrated test to confirm 1MV output by combining invertor systems, DC generators and transmission lines extracted errors/accidents in some components. To realize a concrete system for ITER, solutions for the repair and the improvement of the system were developed. Hence, NBTF is emerging as a necessary facility, due to the large gap with existing injectors, effectively dedicated to identify issues and find solutions to enable successful ITER NBI operations in a time bound fashion.

It has been reported that nitrate supplementation can improve exercise performance. Most of the studies have used either beetroot juice or sodium nitrate as a supplement; there is lack of data on the potential ergogenic benefits of an increased dietary nitrate intake from a diet based on fruits and vegetables. Our aim was to assess whether a high-nitrate diet increases nitric oxide bioavailability and to evaluate the effects of this nutritional intervention on exercise performance. Seven healthy male subjects participated in a randomized cross-over study. They were tested before and after 6 days of a high (HND) or control (CD) nitrate diet (~8.2 mmol∙day−1 or ~2.9 mmol∙day−1, respectively). Plasma nitrate and nitrite concentrations were significantly higher in HND (127 ± 64 µM and 350 ± 120 nM, respectively) compared to CD (23 ± 10 µM and 240 ± 100 nM, respectively). In HND (vs. CD) were observed: (a) a significant reduction of oxygen consumption during moderate-intensity constant work-rate cycling exercise (1.178 ± 0.141 vs. 1.269 ± 0.136 L·min−1); (b) a significantly higher total muscle work during fatiguing, intermittent sub-maximal isometric knee extension (357.3 ± 176.1 vs. 253.6 ± 149.0 Nm·s·kg−1); (c) an improved performance in Repeated Sprint Ability test. These findings suggest that a high-nitrate diet could be a feasible and effective strategy to improve exercise performance.

Chronic HIV infection is associated with low-level inflammation and increased risk of chronic diseases and mortality. The objective was to assess the effects of moderate intensity exercise on metabolic and inflammatory markers in HIV-infected treated persons. This was a pilot study enrolling cART-treated, sedentary persons with metabolic complications in a 12-week protocol, consisting of three sessions per week of 60 min brisk walking with (strength-walk group) or without (walk group) 30 min circuit-training. Assessments at baseline and week 12 (W12) included body morphometrics and total body dual-energy X-ray absorptiometry; lipid and glucose blood profile; plasma level of high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), D-dimer, interleukin-18 (IL-18), soluble CD14, and CD38 and HLA-DR expression on CD4+ and CD8+ T-cells. Forty-nine patients were included and 35 (71%) completed the program: 21 in the walk and 14 in the strength-walk group. At W12, significant improvements were observed of body mass index, waist and hip circumference, and total cholesterol both overall and in the walk group, and of LDL cholesterol in both training groups. In the whole group, significant reductions were observed in hsCRP, IL-6, D-dimer, IL-18, and of CD8+/CD38+/HLA-DR+ cell frequencies. HsCRP and CD8+/CD38+/HLA-DR+ frequency decreased significantly in both training groups when examined separately whereas IL-6 and D-dimer in the walk group only. Brisk walking, with or without strength exercise, could improve lipid profile and inflammatory markers in chronic HIV infection. ACTRN12615001258549, registered 17 November 2015, \"retrospectively registered\" Web address of trial: http://www.ANZCTR.org.au/ACTRN12615001258549.aspx.

In some situations, it is necessary to strengthen or rehabilitate a structure in the short term, but before doing so, a critical analysis of the underlying causes is required to find the best technique to solve the problem. The structural strengthening is used to increase an element’s ability to resist a stress when it no longer meets the original conditions or new necessities of use due to faults, deterioration, thermal variations, and lack of maintenance. The present article aims to evaluate the strengthening of reinforced concrete beams with 0.75 mm thick SAE 1020 steel plates bonded with epoxy-based structural adhesive. The steel plates were attached to the sheared area before and after the beams were taken to the breaking point load. According to the results, it was possible to conclude the effectiveness of the strengthening applied to healthy beams that had its bearing capacity increased up to 50%. The beam that was strengthened after the shear, with a fissure that was restored with epoxy-based structural adhesive, had its load bearing capacity increased by 49.2%. The beams with fissures that were filled with mortar had their bearing capacity decreased by 58.70% if compared with the reference beams, and thus they presented an unsatisfactory performance.

Circular staplers have reduced the incidence of anastomotic leaks in esophagovisceral anastomosis. However, the prevalence of stenosis is greater with staplers than with manual suturing. The aim of this study was to analyze potential risk factors for the onset of anastomotic stenoses and to evaluate their treatment and final outcome. Between 1990 and 1995, 187 patients underwent esophagectomy and esophagogastrostomy with anastomosis performed inside the chest using a circular stapler. Twenty-three patients (12.3%) developed an anastomotic stenosis. The incidence of strictures was inversely related to the diameter of the stapler. Concomitant cardiovascular diseases; morphofunctional disorders of the tubulized stomach, such as those related to duodenogastric reflux; and neoadjuvant chemotherapy were also recognized as significant risk factors. Endoscopic dilatations proved safe and were effective in the treatment of most anastomotic stenoses. To reduce the risk of anastomotic stenosis after stapled intrathoracic esophagogastrostomy, adequate vascularization of the viscera being anastomized should be maintained, and it is mandatory to use the largest circular stapler suitable. Furthermore, it is essential to reduce the negative inflammation-inducing effects of duodenogastroesophageal reflux to a minimum. Endoscopic dilatations are safe and effective in curing the great majority of anastomotic stenoses.

Moderate intensity aerobic activity reduces the risk of cardiovascular disease, diabetes and metabolic syndrome in the general population and has a potential in preventing bone loss. We evaluated the effects of brisk walking, with or without strength exercise, on bone mineral density in HIV‐infected treated persons. Twenty‐eight HIV‐infected, cART‐treated, sedentary subjects with VL<50 c/mL were enrolled in a 12‐week exercise program, consisting of 3 outdoor sessions/week of 60 min walking at 67–70% of HR (heart rate) max±30 min circuit training at 65% of 1‐RM (repetition maximum). Subjects were examined at baseline (BL) and 12 weeks (W12) by 6‐minute walking test (6MWT) and by counting the number of repetitions for each strength exercise; and by dual energy X‐ray absorptiometry (DEXA) to evaluate lumbar spine and femoral bone mineral density with t‐ and z‐scores ‐ in addition to morphometric (BMI, waist, hip and leg circumference) and blood examination (cytometry, fasting total, HDL and LDL cholesterol, triglycerides, glucose, insulin; AST/ALT, ALP, gGT, creatinine, CPK, HbA1c; CD4+ and CD8+, plasma HIV‐RNA). Differences over time were tested by Wilcoxon‐signed rank test and between groups by Mann‐Whitney test. Twenty‐seven (96%) participants (19M, 8F; median 48 y‐o, IQR 43–54; median CD4+624/µL, IQR 478–708; ART with PI: 13 patients, with NNRTI: 7 patients, and including TDF: 15 patients) completed the 12‐week program with a median adherence of 61% (IQR 50–70): 18 in the ‘walk only’ only group and 9 in the ‘walk and strength’ group. At W12, participants showed significant improvement of distance by 6MWT (Table), and of performance in all strength exercises (crunch p=0.023, lat machine p=0.016, chest press p=0.016, leg extension p=0.016, sitting calf p=0.008, leg press p=0.016). DEXA spine z‐score improved significantly in the whole group, and femoral z‐scores in the ‘walk only’ group. There was no z‐score difference at BL between patients with/out PIs, NNRTIs or TDF. However, spine z‐score improved significantly in patients receiving TDF. At W12 BMI, waist circumference, and LDL also improved significantly in the whole group, whereas no significant changes were observed for the other variables, The above 12‐week program improved fitness and bone density in HIV‐infected treated subjects, in addition to some morphometric variables and serum LDL. Brisk walking, with or without strength exercise, might help control the long‐term consequences of cART. BL‐median (IQR) W12‐median (IQR) p Distance at 6MWT (m) 658 (605–691) 715 (IQR 690–830) <0.0001 DEXA spine (z‐score) −1.15 (−1.7/−0.7) −1.05 (−1.4/−0.3) 0.002 DEXA spine (z‐score)(TDF‐treated pts) −1.4 (−1.7/−0.7) −1.3 (−1.55/−0.5) 0.002 DEXA femoral neck (z‐score)(walk only) −0.8 (−1.4/−0.2) −0.5 (−1.2/−0.2) 0.047 DEXA femoral ward (z‐score)(walk only) −1 (−1.9/−0.6) −0.75 (−1.4/−0.2) 0.004 BMI 25.7 (24.6–26.3) 24.9 (21.4−26) 0.0016 Waist circumference (cm) 93 (87−100) 92 (85.5−98.5) 0.029 LDL cholesterol (mg/dL) 126 (113−154.5) 116 (96–137.5) 0.0003